The number on the announcement was $1,132. That was the implied value of each Lumentum share on November 2, when Marvell Technology and Lumentum Holdings announced a definitive all-stock agreement carrying an implied enterprise value of about $115 billion. Five days later, the same arithmetic produces a very different number.
Marvell closed Friday, November 6, at $141.20. The merger agreement fixes the exchange ratio at 4.500 Marvell shares for each Lumentum share, with no collar and no cash component. Multiply the two and the implied value of a Lumentum share stands at about $635.40 as of Friday’s close. That is roughly 44% below the headline figure from Monday’s announcement — a little more than half the deal’s announced value, erased in a trading week, with the agreement itself unchanged.
All prices in this article are dated to the November 6 regular-session close, the latest available at publication. The market was closed on Saturday; nothing here uses a price from after that close.
The arithmetic, and why it moves so fast
Precision first, because the structure of this deal is what makes the repricing possible. The agreement is all stock at a fixed ratio. There is no collar — no band within which the exchange ratio adjusts if Marvell’s share price moves — and no cash election for Lumentum holders. Every $1 move in Marvell’s share price moves the value of the consideration by $4.50 per Lumentum share, in either direction. The $115 billion enterprise value and the $1,132 per-share figure were snapshots taken at the announcement-date price, not amounts locked into the agreement. They were always going to move. The question was how far, and how fast.
The week gave the answer. Marvell’s shares closed at $251.65 on October 28, the last trading day before speculation about a transaction began. They fell after the deal was announced, fell again as analysts reacted, and dropped 16.4% on Thursday, November 5, closing at $133.55. Friday brought a partial recovery: the shares rose 5.7% to close at $141.20, on a day range of $135.34 to $146.32. From the October 28 close, Marvell is down about 44% in seven trading sessions, and about 57% below its 52-week high of $329.88, reached in June.
The same arithmetic applies to the enterprise value. The announcement implied about $102.5 billion of equity value for Lumentum. Scaling that by the ratio of Friday’s close to the October 28 close puts the implied equity value at roughly $57.5 billion. That is a calculation, not a company figure, and it will be wrong again by Monday’s close. But it is the honest way to describe a fixed-ratio deal in a falling market: the price tag is a live number, and it has been falling with the buyer’s stock.
Lumentum trades below even the shrunken price
The more striking number is not Marvell’s. It is Lumentum’s own share price, which closed Friday at $538.59, up 5.7% on the day from a November 5 close of $509.70. Set that against the implied consideration of about $635.40 and the gap is roughly 15%: Lumentum trades about $97 below what the agreement would deliver if it closed at Friday’s Marvell price.
That gap is the market’s price for the deal’s risk. In a fixed-ratio merger, the target’s share price should in principle track the implied value, discounted for the time to closing and the probability that the deal fails. A 15% discount on a transaction expected to close in the first half of calendar 2028 is a wide one. It says investors are charging heavily for the eighteen months between now and closing, for the regulatory review that must happen in between, and for the possibility that the agreement never reaches the finish line at all.
There is a second comparison that makes the point more sharply. Lumentum closed at $913.95 on October 28, before speculation about a transaction began — the unaffected price against which the announced $1,132 figure represented a premium of about 23.9%. Friday’s close of $538.59 is about 41% below that pre-talks price. In other words, a Lumentum holder today holds shares worth substantially less than they were worth before anyone reported that Marvell wanted to buy the company — and substantially less than the deal would pay them at current Marvell prices. The premium has not just evaporated. It has inverted.
That inversion is unusual, and it deserves a plain explanation. Ordinarily, the announcement of a premium offer lifts the target’s shares toward the offer price and holds them there, with the spread reflecting deal risk. Here the target’s shares have fallen below the level they held before the offer existed. The reason is that the two stocks have fallen together, and Lumentum’s fall has outpaced the arithmetic of the offer. The market is not just discounting the deal. It is repricing the whole optical-interconnect trade — the sector-wide surge that took Lumentum’s shares to a 52-week high of $1,143 in early October — and the deal’s fixed ratio means Lumentum holders now ride Marvell’s repricing as well as their own.
The downgrades that started the slide
The week’s selling did not begin with the price action. It began with the analysts. On Monday and Tuesday, two houses moved against Marvell in the same direction. Bank of America downgraded Marvell from Buy to Neutral and cut its price target from $400 to $225, with analyst Vivek Arya citing the burden of the transaction, a potentially prolonged overhang of stock supply from the all-stock financing, and the prospect of a long regulatory review, including in China. TD Cowen cut its rating from Buy to Hold and slashed its target from $350 to $175, pointing to the structure and timing of the takeover and to expected earnings dilution in the deal’s first year. Both downgrades landed within a day of the announcement, and both withdrew bullish recommendations the houses had held before the deal.
The skepticism is not universal, and the split matters. UBS kept its Buy rating with a $350 target, and coverage of the analyst picture noted that about 40 of 45 analysts tracked by LSEG still rate Marvell Buy or Strong Buy. The downgrades are individual views, not a consensus. But they are the views that moved the market this week, and their reasoning is worth separating from the noise around them. Neither house questioned the strategic logic of owning the laser supply chain. Both questioned the financing: the dilution from issuing stock worth tens of billions, the overhang while that stock is absorbed, and the calendar — a closing date eighteen months out, with the consideration unpriced until then.
Marvell, for its part, gave investors a separate piece of news during the week: preliminary revenue for the third quarter of fiscal 2027 that sits inside its existing guidance, with the range narrowed from plus or minus 5% to plus or minus 2% and the midpoint unchanged. The figures are unaudited, and no upward revision accompanied the release. A confirmed midpoint does not answer the questions the deal raises, and the market treated it that way — the stock kept falling through the guidance update and only turned on Friday, along with the broader market.
The calendar, and what it costs to walk away
If the price action is the week’s loudest story, the calendar is the most consequential one. The agreement, dated November 1 and announced November 2, expects closing in the first half of calendar 2028, subject to stockholder approvals from both companies and regulatory clearances. The merger agreement’s initial outside date is 11:59 p.m. Pacific Time on November 1, 2027, extendable to February 1, May 1, and finally August 1, 2028 in specified circumstances where required regulatory approvals have not yet been obtained. That is a runway of up to roughly twenty-one months from signing — a long time for a fixed-ratio deal to live with its consideration unpriced.
The cost of failure is now on the record, and it is worth getting right, because secondary coverage has circulated the figures attached to the wrong triggers. Marvell’s Form 8-K, filed November 2, sets out three separate termination fees. If Lumentum terminates because Marvell’s board withdraws its recommendation, or if Marvell terminates to enter a definitive agreement for a superior proposal, Marvell owes Lumentum a termination fee of $5.8 billion. Lumentum owes a reciprocal $2.9 billion to Marvell in the corresponding circumstances on its side. A separate regulatory termination fee of $3.2 billion is payable by Marvell if the agreement is terminated in specified circumstances related to the failure to close by the outside date, a final and non-appealable legal restraint under U.S. antitrust law or certain other specified antitrust or foreign investment laws, or a final denial of a required approval — and only where the non-regulatory closing conditions are satisfied or capable of being satisfied. A failed shareholder vote does not by itself trigger the regulatory fee. Those are the 8-K’s terms; the three numbers belong to three different failure modes, and they should not be quoted interchangeably.
The regulatory review is the item most likely to shape the timetable, and the least knowable at this stage. The 8-K names the U.S. Hart-Scott-Rodino waiting period and certain other required regulatory approvals without listing every jurisdiction, so readers cannot yet tell which authorities will have the final say. Bank of America’s reference to a possible review in China is the specific concern most often cited. The agreement contemplates that Marvell may offer divestments and other remedies to secure clearances, but it does not require Marvell to accept a remedy materially adverse to the combined business. Until the companies file their proxy statement and the S-4 registration, the list of reviewing authorities remains partly undisclosed.
What has not changed
It is worth stating plainly what the week’s repricing does and does not change about the underlying business. Nothing in the price action alters Lumentum’s reported results. The company released fiscal first-quarter earnings on the same day as the deal announcement: revenue of about $1.26 billion, up 136.5% year over year, led by pump lasers and optical circuit switches, with guidance of about $1.6 billion for the next quarter. Chief executive Michael Hurlston pointed to a second major near-packaged and co-packaged optics win backed by more than $5 billion in purchase commitments. Those are company figures and company characterizations, and they should be read as such. But they are the demand evidence behind the deal’s strategic case, and they have not been revised since Monday.
The supply picture is likewise unchanged. Lumentum said in October that its AI optical components were sold out through nearly 2029, a year further out than the through-2028 window it had given in April, with demand led by hyperscalers building AI clusters faster than the laser supply chain can expand. A change in the share price does not add a wafer line, and a change of ownership would not add one either. The scarcity that made Lumentum valuable enough to command a $115 billion headline is still the scarcity the deal is priced against. What has changed is what the market will pay for exposure to it, and on what timetable.
Nor has the industry structure around the deal shifted. Nvidia remains both a Lumentum customer and a significant investor: in March it announced a $2 billion investment in Lumentum alongside a multibillion-dollar purchase commitment and capacity access rights, and on the same day put $2 billion into Coherent, Lumentum’s main rival. That position — customer, investor, and holder of capacity rights — made the deal complicated before the announcement, and the week’s price action has not simplified it.
What to watch
The signals that will move this story from here are specific. First, the proxy statement and the S-4 filing: they will name the reviewing jurisdictions, set out the shareholder votes, and put the companies’ own case for the deal in front of both sets of owners. Second, the regulatory posture: any statement from an authority, in the United States or elsewhere, about the scope or timetable of review — and any sign of the China review Bank of America flagged. Third, Lumentum’s next quarter: the guided $1.6 billion revenue figure is the first test of whether the demand story behind the valuation is holding. Fourth, Marvell’s share price itself, which is now the deal’s price tag: every $1 move is $4.50 per Lumentum share, and the gap between Lumentum’s market price and the implied value will narrow only when confidence in the closing rises or the calendar shortens. Fifth, the competitive response: whether Broadcom, Coherent, or another rival answers with capacity of its own, or with a consolidation of its own, in the deal’s shadow.
The fair summary is a narrow one. On November 2, Marvell and Lumentum signed a definitive agreement for an all-stock acquisition at a fixed ratio of 4.500 Marvell shares per Lumentum share, implying about $1,132 per share and an enterprise value of about $115 billion. As of Friday’s close, the same ratio implies about $635 per share, and Lumentum’s own shares closed at $538.59 — below the implied value, and about 41% below their price before the deal was ever reported. The agreement is signed but not closed, the consideration is unpriced until it is, and the market spent the week charging for that uncertainty. The technology case for owning the laser factory has not changed. The price of the deal has, by roughly half.
Sources and further reading
Marvell Technology and Lumentum Holdings, “Marvell and Lumentum to Combine, Creating a Category Leader in AI Connectivity,” November 2, 2026 — definitive all-stock agreement; fixed exchange ratio of 4.500 Marvell shares per Lumentum share; implied enterprise value of $115 billion (approximately $1,132 per share, approximately 23.9% premium to October 28 unaffected closes); pro forma ownership approximately 67% Marvell / 33% Lumentum, fully diluted; expected close in the first half of calendar 2028, subject to stockholder and regulatory approvals and other customary conditions. Marvell Technology, Form 8-K, Item 1.01, filed November 2, 2026 (SEC EDGAR) — merger agreement dated November 1, 2026; outside date November 1, 2027, extendable to February 1, May 1, and August 1, 2028; Marvell termination fee $5.8 billion, Lumentum termination fee $2.9 billion, regulatory termination fee $3.2 billion payable by Marvell in specified regulatory-failure circumstances. Lumentum Holdings, fiscal first-quarter 2027 earnings release, November 2, 2026 — revenue approximately $1.26 billion, up 136.5% year over year; next-quarter guidance approximately $1.6 billion; second major near-packaged/co-packaged optics win backed by more than $5 billion in purchase commitments. Market data: Marvell (NASDAQ: MRVL) closed $141.20 on November 6, 2026, up 5.7% from $133.55 on November 5, day range $135.34–$146.32; October 28 close $251.65; 52-week high $329.88. Lumentum (NASDAQ: LITE) closed $538.59 on November 6, 2026, up 5.7% from $509.70 on November 5; October 28 close $913.95; 52-week high $1,143. Prices via Finnhub and MarketBeat, as of the November 6 regular-session close. Bank of America downgrade (Buy to Neutral, target $400 to $225) and TD Cowen downgrade (Buy to Hold, target $350 to $175), with UBS holding Buy at $350, as reported November 3–4, 2026. Nvidia’s $2 billion Lumentum investment and capacity access rights, March 2, 2026, and Lumentum’s sold-out-through-nearly-2029 window are as covered in this publication’s October 29 article, “Marvell Wants to Buy the Laser Company — an $83 Billion Optical Land Grab.” Implied per-share values and the implied enterprise-value arithmetic are calculations from the fixed 4.500 ratio and the stated closes, not company figures. This article is analysis, not investment advice.